Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$48.4MCash on Hand
17.3mo Cash Runway
Follow RANI by emailGet an email when RANI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RANI, unsubscribe in one click. Privacy
📣 What RANI Says Is Next
by the end of 2026 · “We have continued to advance the program in the clinic, with additional data from the dose expansion cohort expected by the end of 2026.” “We also continued to expand our obesity franchise through a new collaboration with PegBio leveraging the RaniPill platform to explore the oral delivery of novel obesity and metabolic disease molecules across multiple mechanisms of action,” continued Imran.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Listing Nasdaq approved Rani's transfer from the Global Market to the Capital Market and extended its deadline to regain the $1.00 minimum bid price until May 10, 2027. The transfer took effect November 12, 2026, and the stock keeps the RANI symbol. Form 8-K · SEC filing
Nov 9, 2026 ·
Earnings Reported Q3 2026 results: cash and marketable securities of $45.3 million as of September 30, 2026, funding expected through end of 2027. Contract revenue was $1.7 million, and net loss was $8.8 million. Also announced acceptance into the FDA's Emerging Technology Program in October. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Aug 13, 2026 ·
Earnings Reported Q2 2026 results: cash and marketable securities of $53.4 million at June 30, 2026, with cash expected to last through 2027; net loss of $8.4 million versus $11.2 million a year earlier. Also issued a corporate update on RT-114 expansion cohort dosing and the PegBio collaboration. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1 · Recruiting · An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers. Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not RANI's own candidates): Teriparatide, Ustekinumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RANI holds $48.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.4M/quarter from operations,
an estimated runway of 17.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:43 · Elevated
Cash runway 17 months +18
ATM program on file since May 2025 +15
Shelf registration (S-3, Aug 2025) +10
Recent financing filings on SEC EDGAR:
May 27, 2026 · Registered direct / best-efforts offering · 424B5
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RANI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.